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Abstract 
Objective: To describe the liver disease epidemiology among HIV-infected individuals in Zambia.  
Methods: We recruited HIV-infected adults (≥18 years) at antiretroviral therapy initiation at two fa-
cilities in Lusaka. Using vibration controlled transient elastography we assessed liver stiffness, a sur-
rogate for fibrosis/cirrhosis, and analyzed liver stiffness measurements (LSM) according to estab-
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lished thresholds (>7.0 kPa for significant fibrosis and >11.0 kPa for cirrhosis). All participants un-
derwent standardized screening for potential causes of liver disease including chronic hepatitis B 
(HBV) and C virus co-infection, herbal medicine, and alcohol use. We used multivariable logistic re-
gression to identify factors associated with elevated liver stiffness. 
Results: Among 798 HIV-infected patients, 651 had a valid LSM (median age, 34 years; 53% female). 
HBV co-infection (12%) and alcohol use disorders (41%) were common and hepatitis C virus co-
infection (<1%) was rare. According to LSM, 75 (12%) had significant fibrosis and 13 (2%) had cirrho-
sis. In multivariable analysis, HBV co-infection as well as male sex, increased age, and WHO clinical 
stage 3 or 4 were independently associated with LSM >7.0 kPa (all P<0.05). HBV co-infection was the 
only independent risk factor for LSM >11.0 kPa. Among HIV-HBV patients, those with elevated ALT 
and HBV viral load were more likely to have significant liver fibrosis than patients with normal mark-
ers of HBV activity. 
Conclusions: HBV co-infection was the most important risk factor for liver fibrosis and cirrhosis and 
should be diagnosed early in HIV care to optimize treatment outcomes. 
 
Keywords: HIV/AIDS, Africa, liver fibrosis, hepatitis B virus, transient elastography, alcohol use disor-
der 
 
Introduction 
In high-income settings advanced liver disease is a leading cause of mortality among HIV-infected in-
dividuals, primarily due to chronic viral hepatitis co-infection. In the D:A:D study of HIV-infected pa-
tients taking antiretroviral drugs in Europe, Australia, and Argentina, 14.5% of deaths were liver dis-
ease-related as a result of decompensated cirrhosis, and/or hepatocellular carcinoma.1 Among those 
who died from liver disease, 17% had chronic hepatitis B virus (HBV) and 66% had hepatitis C virus 
(HCV).1 In the Multicenter AIDS Cohort Study in the United States, men who were dually HIV- and 
HBV-infected had 8 times higher liver-related mortality than those with HIV alone.2,3   
HIV-infected individuals in sub-Saharan Africa (SSA) may be at higher risk of developing liver fi-
brosis and cirrhosis from various factors. In SSA, the prevalence of HBV co-infection reaches 10-15% 
in the general population, and three million individuals are estimated to be dually infected with HIV 
and HBV.4 In these settings, chronic HBV is most commonly acquired in early childhood and was in-
consistently found to be a risk factor for liver fibrosis.5,6 Fibrosis may also be caused by environmen-
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tal exposure to aflatoxins and by certain traditional herbal medicines. In rural Uganda, for example, 
HIV-infected patients who reported herbal medicine use had 2-5 fold higher rates of liver fibrosis.7 
Schistosomiasis is also endemic in SSA and contributes to the burden of periportal fibrosis and portal 
hypertension.8 
 
Due to limited access to diagnostic tests for liver fibrosis/cirrhosis in SSA, the causes of liver dis-
ease are poorly understood among HIV-infected populations. Although the most advanced cases are 
diagnosed clinically, the diagnosis historically required a liver biopsy, which is unavailable outside of 
major referral centers due to its invasive nature, the requirement for a pathologist to interpret he-
patic histology, and the potential complications. To reduce the need for biopsy, blood and imaging 
tests for liver fibrosis have been developed, including transient elastography (TE, Fibroscan®), which 
has been used in several recently published studies in Africa5,9,10 and recommended by WHO in man-
agement of HBV11 and HCV.12 Using TE, we measured liver stiffness in a relatively large cohort of HIV-
infected, antiretroviral therapy (ART)-naïve Zambian adults and investigated possible risk factors for 
liver fibrosis/cirrhosis.    
 
Methods 
Study setting and patients 
In two public sector HIV treatment facilities in Zambia’s capital Lusaka we recruited HIV-infected 
adults (18+ years old) who were eligible for ART into a prospective cohort study. According to local 
guidelines at the time, patients were ART eligible if they had WHO clinical stage 3 or 4 disease 
and/or a CD4+ count of <350 cells/mm3 prior to April 2014 after which eligibility expanded to all pa-
tients with a CD4+ count <500 cells/mm3.13 Patients who intended to transfer care to a facility out-
side of Lusaka within 12 months of ART initiation were excluded from participation. This study was 
implemented within the framework of the International Epidemiologic Databases to Evaluate AIDS in 
Southern Africa (IeDEA-SA), a large regional network of HIV treatment programs that pools and ana-
lyzes standardized and anonymized datasets.14 The ethics committees of the University of Zambia 
(Lusaka, Zambia) and University of North Carolina at Chapel Hill (North Carolina, USA) approved this 
study (clinicaltrials.gov identifier NCT02060162) and all patients provided informed consent prior to 
participation. 
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Laboratory measurements 
In addition to WHO staging and CD4+ testing at enrollment, we measured height, weight, ALT, AST, 
creatinine, and platelet count. Using rapid point-of-care tests in the clinic we screened patients for 
hepatitis B surface antigen (HBsAg; Determine HBsAg, Alere Inc., Massachusetts, USA) using finger 
prick sampling and for hepatitis C antibody (Oraquick HCV, Orasure Technologies, Pennsylvania, USA) 
using an oral swab kit. Patients were defined as HBV co-infected if the HBsAg test was positive. 
Among HBV co-infected individuals, we measured hepatitis B e antigen (HBeAg) and HBV DNA levels 
(Roche COBAS AmpliPrep/COBAS TaqMan HBV Test version 2.0; limit of detection, 20 IU/ml). We al-
so determined HBV genotype using an in-house Sanger sequencing assay.15-17 Nucleotide sequences 
were analyzed with Sequencher version 5.0 (Gene Codes Corporation, Michigan, USA) and the 
Geno2Pheno (www.geno2pheno.org) platform was used to predict HBV genotypes. 
 
Assessment of liver stiffness 
Liver fibrosis/cirrhosis was assessed in non-pregnant patients using TE according to manufacturer 
guidelines (Echosens, Paris, France). With patients lying supine with their right arm abducted, at 
least 10 valid liver stiffness measurements (LSM) were made of the right lobe of the liver. Measure-
ments were made by 1 of 3 operators who received manufacturer-recommended training. We classi-
fied TE as very reliable if the interquartile range divided by median (IQR/M) was <0.1, reliable if 
IQR/M was 0.1-0.3, and poorly reliable if IQR/M was >0.3.18 We defined significant hepatic fibrosis 
(corresponding to Metavir stages F2-F4) as median LSM >7 kPa and cirrhosis (Metavir stage F4) as 
median LSM >11 kPa. These thresholds were suggested in the WHO guidelines for treatment of hep-
atitis B virus in resource-limited settings.11 In secondary analyses we considered high LSM thresholds 
(>9.3 kPa for significant fibrosis and >12.3 kPa for cirrhosis) that were used in other liver fibrosis 
studies in SSA and based on validation studies in Europe and the U.S.5,9 
 
Other study procedures 
Using a standardized questionnaire we screened for potential causes of elevated liver stiffness in-
cluding anti-tuberculosis treatment, current herbal medicine use, regular exposure to freshwater 
lakes or rivers (a surrogate for schistosomiasis), and alcohol use. We assessed current and recent al-
cohol consumption using the World Health Organization’s Alcohol Use Disorders Identification Test 
consumption questions (AUDIT-C),19 an instrument that has been used in other African settings.20 
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Each alcoholic beverage was standardized to a local beer that contained 10 grams of alcohol per 12-
ounce bottle. We defined a possible alcohol use disorder as an AUDIT-C score of ≥3 points for wom-
en and ≥4 for men.19  
 
Statistical analyses 
Among patients with a valid TE result, we compared baseline characteristics between HBsAg positive 
and negative participants using Wilcoxon rank sum tests for continuous variables and Chi square 
tests for categorical ones. We categorized body mass index as <18.5, 18.5-25, and >25 and CD4+ 
count as <100, 100-199, 200-350, and >350 cells/mm3. We investigated the association between 
HBsAg-positivity and significant fibrosis and cirrhosis using multivariable logistic regression, adjusted 
for all factors associated with fibrosis or cirrhosis in univariable analyses as well as those identified a 
priori from literature review. Among HIV-HBV co-infected patients, we described the proportion with 
hepatic fibrosis and cirrhosis according to HBV viral load and ALT level. We used Stata version 12 
(Statacorp, College Station, Texas) for data analysis.  
 
Results 
From October 2013 to August 2014, we enrolled 798 HIV-infected treatment-naïve adults in the co-
hort study and 653 had TE at enrollment. The main reasons for a missing TE result were pregnancy 
as a contraindication (n=25), or enrollment at time when the instrument was unavailable (n=118). TE 
was invalid in two cases with the remaining 651 (82%) comprising the analysis cohort. Patients ex-
cluded from the analyses because of unavailability of TE had similar age, sex, WHO clinical stage, 
HBsAg status, and CD4+ count compared to those who received the test (all P>0.05).  
Within the analysis cohort, the median age of participants was 34 years (interquartile range 
[IQR] 29-40), 343 (52.7%) were women, and the median CD4+ count was 229 cells/mm3 (IQR 122-
336) at the time of ART initiation. HBsAg-positivity was relatively common (n=98, 12.4%) but anti-
hepatitis C antibody positivity was rare (n=1, <1%). No current or recent alcohol consumption (i.e., 
AUDIT-C score of 0) was reported by 360 (55.1%), moderate consumption (AUDIT-C of 1-2 for wom-
en and 1-3 for men) was reported by 25 (3.8%), and 268 (41.2%) reported levels of drinking con-
sistent with a possible alcohol use disorder (58.9% of men versus 25.2% of women, P<0.001). Cur-
rent use of at least one herbal medicine was reported by 103 (15.8%) participants. A full description 
of the characteristics of the analysis cohort is displayed in Table 1.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Among HBV co-infected patients, 19 (29.7%) were hepatitis B e antigen positive, the median 
HBV viral load was 3.7 (2.1-6.4) log10 IU/ml, and 53.6% had HBV viral loads >2,000 IU/ml. HBV geno-
type was A1 for 29 patents, E for 28 patients, and 1 patient had mixed infection with A1 and E. Com-
pared to their HBsAg-negative counterparts, HBV co-infected patients were more likely to be male, 
to have alcohol use disorder, had higher median ALT but similar median CD4+ counts. Age and sex 
distribution were similar in both study groups (Table 1).  
 Across the 651 assessments of liver stiffness, based on IQR/M, TE was very reliable in 357 
(54.8%), reliable in 289 (44.4%), and poorly reliable in 5 (0.8%). Median LSM was 5.1 kPa (IQR 4.4-
6.1), 75 (11.5%) had LSM >7 kPa consistent with significant hepatic fibrosis, and 13 (2.0%) had LSM 
>11 kPa consistent with cirrhosis. The proportion with significant fibrosis according to patient de-
mographics and selected clinical characteristics are displayed in Figure 1. Patients who reported haz-
ardous levels of alcohol consumption had similar median LSM (5.2 kPa) and a similar percentage 
with LSM >7.0 (11.7%) as non-drinkers (median LSM, 5.0 kPa; 11.2%). In multivariable analyses, 
HBsAg-positivity was associated with significant liver fibrosis (adjusted odds ratio [AOR] 2.84; 95% 
confidence interval [CI], 1.48-5.46). Other risk factors for LSM >7 kPa included age 40+, male sex, and 
WHO clinical HIV stage 3 or 4 (all P<0.05). HBsAg-positivity was the only statistically significant pre-
dictor of cirrhosis (AOR 7.31; 95% CI, 2.14-24.59; Table 2). At thresholds of LSM >9.3 for significant 
fibrosis and >12.3 for cirrhosis, point estimates in the models were similar (Supplementary table), 
but only HBsAg-positivity remained significantly associated with the outcomes.  
Among HBV co-infected patients, significant fibrosis was more common in those with elevated 
ALT (23.6% versus 8.8%, P=0.083), positive HBeAg (42.1% versus 22.2%, P=0.08), or HBV viral loads 
>20,000 IU/ml (31.2% versus 20.4%, P=0.32). When stratified by ALT levels (normal or elevated) and 
HBV viral load (≤20, 20-2,000, or >2,000 IU/ml), we observed a significant trend toward higher liver 
stiffness level with increases in both (P=0.04; Figure 2).    
 
Discussion 
Among HIV-infected patients in Lusaka, Zambia, HBsAg-positivity was a strong predictor of liver fi-
brosis and cirrhosis at the time of ART initiation and this association increased with markers of HBV 
severity. Increased age, male sex, and advanced clinical stage of HIV infection were also linked with 
elevated liver stiffness. These data suggest that HBV co-infection should be diagnosed early during 
HIV care and that interventions to identify and manage liver disease in HIV programs in SSA could be 
tailored to specific groups. 
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Our findings are consistent with those of other African studies. At a public facility in Nigeria, 325 
HIV-infected adult patients (including 93 with HIV-HBV) underwent a cross-sectional assessment of 
liver fibrosis using TE.5 HIV-HBV co-infected patients had 5 times the odds of significant fibrosis com-
pared to those with HIV alone. Similar to our findings, HBV viral load was a strong correlate of ele-
vated stiffness measurement, supporting recommendations that HIV-HBV patients be treated with 
ART regimens that contain tenofovir, the most potent anti-HBV drug available.21 More recently, 
among 106 HIV-HBV patients taking lamivudine-based ART in Ghana, 24 (22.6%) had advanced fibro-
sis or cirrhosis by TE. Most patients were switched to a tenofovir-containing regimen and during 8 
months of follow-up, levels of liver stiffness fell,10 suggesting a potential role for TE in longitudinal 
assessment of liver disease where the device is available. 
In addition to HBV, we observed that men were more likely to have elevated liver stiffness. 
Women may have had relatively lower liver stiffness because of the protective effects of estrogen in 
hepatic fibrogenesis.22 Although alcohol abuse disorders were not linked to LSM in the study, men 
were more likely to report alcohol use and this could explain their doubling of fibrosis compared to 
women. Worldwide alcohol is a leading cause of cirrhosis; however, in our cohort an elevated AU-
DIT-C score was not linked with liver stiffness for several potential reasons. First, in our experience, 
quantifying an individual’s alcohol intake in Zambia can be challenging because the most common 
form of alcohol, maize/sorghum beer, can have variable alcohol concentration and drinks are shared 
within a group.23 Further, in our study, assessment of alcohol use was done at the time of ART initia-
tion and we suspect that many recent drinkers had abstained for a period of weeks to months as 
they were HIV tested, linked to care, and assessed for ART eligibility. Therefore, the hepatic effects 
of heavy drinking such as steatohepatitis may have receded prior to our assessment of liver fibrosis. 
Despite these results, screening for alcohol use disorders remains an important intervention as 
heavy drinking was highly prevalent. 
This study had a number of strengths. First, we demonstrated the feasibility of screening for liv-
er fibrosis and cirrhosis using TE, a relatively novel non-invasive test that has been used in a very lim-
ited number of studies in SSA.5,9,10,24 Despite limited availability in SSA, WHO guidelines for HBV11 and 
HCV12 treatment in LMIC recommend TE for fibrosis staging when available. Our sample was recruit-
ed among treatment naïve patients at two large clinics in Lusaka and the data are likely representa-
tive of other urban populations in the region. Another strength of the study was comprehensive 
screening of hepatitis C virus, traditional/herbal medicine use, and alcohol abuse disorders. Finally, 
detailed analyses of the virologic and serologic characteristics of HBsAg-positive individuals add to 
the scarce literature on HIV-HBV in this region. 
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Our study also had weaknesses. Because of pregnancy and unavailability of TE, nearly 20% of 
our cohort did not have a baseline assessment of LSM. However, we do not expect this to have sig-
nificantly biased our analyses as there were no major differences in the baseline characteristics of 
these patients compared to those analyzed. Although it is widely recommended for liver fibrosis as-
sessment, TE is imperfect and has not been validated in HIV-infected cohorts in SSA. Rather than fo-
cus our analysis on the prevalence of fibrosis/cirrhosis, we investigated risk factors for high LSM, 
considering various thresholds. We believe this approach provided evidence regarding the useful-
ness of TE in SSA settings. For settings where TE is not available, more investigation is needed into 
blood indices that depend on low cost tests, such as AST-to-platelet ratio,6,25 FIB-4,26 and GGT-to-
platelet ratio.27 Finally, we did not comprehensively assess patients for other potential causes of liver 
fibrosis such as hepatosplenic schistosomiasis or aflatoxin exposure. 
In summary, among treatment naïve HIV-infected adults in Lusaka, Zambia, HBV co-infection 
was the most important risk factor for elevated liver stiffness. Liver-related mortality among HIV-
infected individuals is often preceded by fibrosis and cirrhosis. Therefore, among HIV-HBV patients, 
liver fibrosis assessment using TE or other non-invasive tests may be considered a viable technique 
to optimize care of this at risk group. 
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Figure legends 
FIGURE 1. Proportion of individuals with elevated liver stiffness, stratified by baseline characteristics 
FIGURE 2. Liver stiffness score according to markers of hepatitis B virus (HBV) severity among 81 
HIV-HBV co-infected patients 
 
Table 1. Sociodemographic and clinical characteristics of 651 HIV-infected 
Zambian adults with a valid liver stiffness measurement at the time of an-
tiretroviral therapy initiation 
 HBsAg-negative 
(n=570) 
HBsAg-positive 
(n=81) P value 
Age, years 34 (30-40) 34 (28-39) 0.475 
Female sex 307 (53.9) 35 (43.2) 0.072 
Education level  
     None to grade 6 
     Grades 7-12 
     College/University 
 
136 (24.1) 
164 (28.9) 
266 (47.1) 
 
17 (21.5) 
21 (26.6) 
41 (51.9) 
 
0.722 
Body mass index 20 (18-22) 20 (19-23) 0.187 
WHO clinical stage 
     1 or 2 
     3 or 4 
 
291 (51.5) 
274 (48.5) 
 
45 (56.2) 
35 (43.8) 
 
0.426 
Tuberculosis 95 (16.7) 12 (14.8) 0.674 
CD4+ count, cells/mm3 226 (121-331) 233 (128-378) 0.475 
Anti-HCV positive 0 (0) 1 (1.2) — 
ALT, U/L 19 (14-27) 23 (13-40) 0.025 
AST, U/L 31 (25-41) 35 (26-60) 0.057 
HBeAg positive — 19 (30.0) — 
HBV viral load, log IU/ml — 3.7 (2.1-6.4) — 
Herbal medicine use 88 (15.4) 15 (18.5) 0.477 
Alcohol consumptionb 
     None 
     Moderate 
     Alcohol use disorder 
 
324 (56.8) 
20 (3.5) 
226 (39.7) 
 
34 (42.0) 
5 (6.2) 
42 (51.8) 
 
0.035 
Occupational fishing 132 (23.2) 27 (33.3) 0.046 
All values are median (interquartile range) or number (%). 
bAlcohol consumption was defined by consumption questions from Alcohol Use Disorders 
Identification Test (AUDIT-C). No drinking was defined as AUDIT-C score of 0, moderate 
drinking was AUDIT-C score of 1-2 for women and 1-3 for men, and alcohol use disorder 
was AUDIT-C score of 3-12 for women and 4-12 for men. 
Abbreviations: HBsAg, hepatitis B surface antigen; WHO, World Health Organization; 
HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
HBeAg, hepatitis B e antigen; HBV, hepatitis B virus
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Table 2. Risk factors for significant fibrosis (>7kPa) and cirrhosis (>11 kPa) based on 
transient elastography among HIV-infected Zambian adults 
 Significant fibrosis Cirrhosis 
Crude 
OR (95% CI) 
Adjusted 
OR (95% CI) 
Crude 
OR (95% CI) 
Adjusted 
OR (95% CI) 
Age, years 
     18-29  
     30-39 
     40+ 
 
Reference 
2.22 (1.14-
4.35) 
2.60 (1.27-
5.32) 
 
Reference 
1.94 (0.91-
4.13) 
2.80 (1.26-
6.24) 
 
Reference 
1.46 (0.37-
5.72) 
1.09 (0.22-
5.49) 
 
Reference 
2.01 (0.38-
10.57) 
1.47 (0.21-
10.08) 
Sex 
     Female 
     Male 
 
Reference 
3.43 (2.03-
5.79) 
 
Reference 
2.94 (1.61-
5.39) 
 
Reference 
3.77 (1.03-
13.83) 
 
Reference 
2.81 (0.66-
11.96) 
Body mass index 
     18 and over 
     <18 
 
Reference 
1.31 (0.77-
2.24) 
 
Reference 
1.26 (0.69-
2.31) 
 
Reference 
2.24 (0.72-
6.94) 
 
Reference 
2.29 (0.63-
8.31) 
WHO clinical stage 
     1 or 2 
     3 or 4 
 
Reference 
1.90 (1.04-
3.48) 
 
Reference 
1.76 (0.97-
3.22) 
 
Reference 
6.31 (1.39-
28.68) 
 
Reference 
4.09 (0.76-
21.86) 
Tuberculosis 2.04 (1.18-
3.51) 
1.27 (0.66-
2.04) 
2.31 (0.70-
7.64) 
1.74 (0.48-
6.32) 
HBsAg-positive 2.34 (1.32-
4.13) 
2.84 (1.48-
5.46) 
5.82 (1.91-
17.70) 
7.31 (2.14-
24.59) 
CD4+ count, 
cells/mm3 
     200+ 
     <200 
 
Reference 
1.54 (0.95-
2.49) 
 
Reference 
1.19 (0.70-
2.04) 
 
Reference 
0.77 (0.25-
2.38) 
 
Reference 
0.40 (0.11-
1.44) 
Alcohol use disorder 1.04 (0.65-
1.68) 
0.67 (0.38-
1.18) 
0.63 (0.19-
2.06) 
0.36 (0.09-
1.39) 
Occupational fishing 2.03 (1.23-
3.59) 
1.57 (0.90-
2.75) 
2.72 (0.90-
8.21) 
2.30 (0.70-
7.62) 
Herbal medicine use 1.26 (0.67-
2.38) 
1.34 (0.69-
2.62) 
0.44 (0.05-
3.40) 
0.37 (0.04-
3.17) 
Abbreviations: kPa, kilopascals; OR, odds ratio; WHO, World Health Organization  
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